Patient guide · Reviewed May 2026
Non-Invasive Liver Tests in Australia — Alternatives to Liver Biopsy
Liver biopsy was once the only definitive way to assess liver health — a needle inserted through the skin to extract a small core of liver tissue for laboratory analysis. It is still the gold standard for definitive diagnosis. But for most patients, non-invasive alternatives now provide sufficient clinical information without the risk, cost, and discomfort of an invasive procedure.
This guide covers the non-invasive liver tests available in Australia, what each one measures, and when each is appropriate.
Published 2026-05-31 · Clinically reviewed 2026-05-31
Patient guide · Reviewed May 2026
Why Non-Invasive Testing Matters
Liver biopsy has significant drawbacks that make it unsuitable for routine or repeated liver assessment:
Liver biopsy has significant drawbacks that make it unsuitable for routine or repeated liver assessment:
- Risk: Approximately 1 in 1,000 biopsies cause serious complications including significant bleeding, infection, or inadvertent puncture of adjacent structures
- Cost: $1,500–$3,000+ including procedure, day surgery or hospital admission, pathology, and anaesthesia
- Sampling error: Each biopsy samples approximately 1/50,000th of the total liver volume — fibrosis can be unevenly distributed, causing staging errors
- Recovery: Most patients require 4–6 hours of observation post-procedure and may have residual discomfort for several days
- Frequency: Due to the above, biopsy cannot be repeated routinely for monitoring — making it unsuitable for serial assessment of treatment response
Non-invasive tests address all of these limitations. They are safe for repeated use, significantly cheaper, produce results immediately, and carry no procedural risk.
1. FIB-4 Score (Blood Test)
What it measures: Probability of significant liver fibrosis, calculated from age, ALT, AST, and platelets.
How it works: A mathematical formula applied to results from a standard blood panel. No additional testing required.
Result: Score below 1.3 = low risk. 1.3–2.67 = indeterminate. Above 2.67 = high risk.
Cost: No additional cost — uses existing blood test results.
Best for: First-line screening of at-risk populations in primary care. The starting point of the Australian MASLD assessment pathway.
Limitation: Does not provide a direct fibrosis stage measurement. The indeterminate range (1.3–2.67) affects a large proportion of at-risk patients and requires further testing.
Patient guide · Reviewed May 2026
2. Transient Elastography (FibroScan / Guided Elastography)
What it measures: Liver stiffness (kPa) as a proxy for fibrosis stage. Most devices also measure liver fat content (CAP or UAP score).
What it measures: Liver stiffness (kPa) as a proxy for fibrosis stage. Most devices also measure liver fat content (CAP or UAP score).
How it works: A probe sends a mechanical pulse through the skin over the right side of the abdomen. The speed of the pulse through liver tissue indicates stiffness. The scan takes 10–15 minutes.
Result: kPa below 8 = F0–F1 (minimal fibrosis). 8–10 = F2. 10–13 = F3. Above 13 = F4 range.
Cost: $150–$300 at private Australian clinics.
Best for: Second-line assessment after indeterminate FIB-4. Monitoring MASLD progression and treatment response. Serial assessment of patients on GLP-1 therapy for MASH.
Limitation: Accuracy decreases at higher BMI with standard probe. Active liver inflammation can falsely elevate stiffness readings. Requires fasting.
3. Enhanced Liver Fibrosis Panel (ELF Test)
What it measures: Three direct markers of fibrosis activity in the blood — hyaluronic acid, PIIINP, and TIMP-1.
How it works: A standard blood draw sent to a reference laboratory.
Result: ELF score below 7.7 = low risk. 7.7–9.8 = moderate risk. Above 9.8 = high risk.
Cost: Approximately $50–$150 at reference laboratories.
Best for: Complement to elastography in specialist settings. Particularly useful for serial monitoring of fibrosis activity in patients already under specialist care.
Limitation: Not yet part of routine GP referral pathways in Australia. Requires reference laboratory processing — not immediately available.
Patient guide · Reviewed May 2026
4. Liver Ultrasound
What it measures: Liver anatomy and echogenicity (brightness). A bright liver indicates fat accumulation.
What it measures: Liver anatomy and echogenicity (brightness). A bright liver indicates fat accumulation.
How it works: Standard abdominal ultrasound with gel applied to the abdomen.
Result: Normal, mildly echogenic, moderately echogenic, or severely echogenic liver. Cannot grade fibrosis.
Cost: $100–$250. May attract Medicare rebate.
Best for: Initial detection of hepatic steatosis. Ruling out other liver pathology (masses, vascular abnormality). Not suitable for fibrosis staging.
Limitation: Cannot measure fibrosis — the most important prognostic factor. Cannot quantify fat content precisely. Operator-dependent.
5. 2D Shear Wave Elastography (2D-SWE)
What it measures: Liver stiffness using a different mechanical wave approach, providing a colour-coded stiffness map of the liver.
How it works: Available on high-end ultrasound machines. Generates quantitative kPa measurement alongside real-time colour map.
Cost: $200–$400 at specialist centres.
Best for: Specialist hepatology settings with 2D-SWE capable equipment. Research settings.
Limitation: Not universally available. Different reference ranges to FibroScan. Less widely validated across all liver disease subtypes.
Patient guide · Reviewed May 2026
6. MRI Elastography (MRE)
What it measures: Liver stiffness across the entire liver volume, plus liver fat content (proton density fat fraction — PDFF).
What it measures: Liver stiffness across the entire liver volume, plus liver fat content (proton density fat fraction — PDFF).
How it works: Standard MRI with additional elastography sequences. Takes 30–45 minutes.
Cost: $500–$900+ at specialist centres.
Best for: Complex cases where FibroScan is inconclusive. Patients with very high BMI where ultrasound-based elastography is unreliable. Research and clinical trial settings.
Limitation: Expensive. Limited availability. Requires MRI-compatible patients. Not practical for routine monitoring.
The Australian Testing Pathway — Non-Invasive First
Australian clinical guidelines recommend a stepped non-invasive approach:
- Step 1: FIB-4 from routine bloods (GP)
- FIB-4 below 1.3 → Reassure. Repeat 3 years.
- FIB-4 1.3–2.67 → Transient elastography (FibroScan/guided)
- FIB-4 above 2.67 → Hepatologist referral ± specialist testing
- Elastography result
- Below 8 kPa → Reassure. Annual LFTs.
- 8–13 kPa → Specialist review. Treat if MASH F2–F3.
- Above 13 kPa → Urgent specialist referral.
Liver biopsy is reserved for cases where non-invasive tests are inconclusive and management decisions require certainty — typically less than 5% of patients in the pathway.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
What is the most accurate non-invasive liver test?
MRI elastography provides the most accurate non-invasive fibrosis assessment but is expensive and limited in availability. For routine clinical use, the combination of FIB-4 and transient elastography (FibroScan or guided elastography) provides sufficient accuracy at accessible cost.
Can a blood test diagnose liver fibrosis?
The FIB-4 blood test stratifies risk of fibrosis but does not provide a direct fibrosis stage. It is a screening tool rather than a diagnostic test. Patients in the indeterminate range require elastography for definitive staging.
Is transient elastography (FibroScan) as accurate as biopsy?
For detecting significant fibrosis (F2 and above), transient elastography has high accuracy with AUROC values typically above 0.85. For very early fibrosis (F1) and for definitively diagnosing MASH (inflammation), biopsy remains more accurate. For routine clinical management of MASLD, elastography provides sufficient information without biopsy in the majority of patients.
Do I need a GP referral for a non-invasive liver test?
The FIB-4 score requires a blood test ordered by a GP or registered healthcare provider. Liver elastography can be self-referred at several Australian clinics. Check with your specific clinic when booking.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or submit an appointment request and we will route you to the nearest available provider.